{"product_id":"johns-hopkins-wilmer-eye-institutes-macula-and-the-5th-annual-retina-festival-2025","title":"Johns Hopkins Wilmer Eye Institute’s MACULA and the 5th Annual Retina Festival 2025","description":"\u003ch3\u003eJohns Hopkins Wilmer Eye Institute’s MACULA and the 5th Annual Retina Festival 2025\u003c\/h3\u003e\n\u003cstrong\u003eInclude: 9 videos + 1 pdf, size: 5.12 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e Target Audience: ophthalmologists\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e Information:\u003c\/strong\u003e\n\u003cbr\u003e\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"activitysectionbold\"\u003e\n\u003cbr\u003e\u003cbr\u003eDate \u0026amp; Location Saturday, January 11, 2025, 7:30 AM – 5:00 PM, Johns Hopkins University School of Medicine, Turner Bldg., Baltimore, MD\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"activitysectionbold\"\u003eTarget Audience \u003cem\u003eSpecialties\u003c\/em\u003e – Ophthalmology\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv class=\"activitysectionbold\"\u003eOverview\u003c\/div\u003e\n\u003cbr\u003eOver the past several years, there is a growing body of medical evidence demonstrating a clear biologic rationale for targeting vascular endothelial growth factors in the treatment of the neovascular form of age related macular degeneration, diabetic retinopathy, and related diseases. Furthermore, there are new imaging and therapeutic approaches to vitreomacular interface abnormalities, intraocular tumors, posterior uveitis, hereditary retinal degenerations, as well as surgical diseases of the retina.\u003cbr\u003e\u003cbr\u003eThese areas of investigation are relatively new, and most ophthalmologists are not aware of the myriad of new clinical trials relevant to these diseases. Thus, these subjects are areas of great interest both to ophthalmologists who treat these diseases and to those who refer these cases for further management. Presentations were chosen to emphasize new information and consensus on the use of these biologic agents to treat the neovascular and non-neovascular forms of age-related macular degeneration, vitreomacular interface abnormalities, diabetic retinopathy, intraocular tumors, and posterior uveitis. In addition, cases were chosen highlighting new information being reported by randomized clinical trials in these disease areas.\u003cbr\u003e\u003cdiv class=\"activitysectionbold\"\u003eObjectives\u003c\/div\u003e\n\u003col\u003e\n\u003cli\u003eExplain the biologic rationale for targeting vascular endothelial growth factors in the treatment of the neovascular form of age-related macular degeneration, diabetic retinopathy, and related diseases.\u003c\/li\u003e\n\u003cli\u003eDiscuss new imaging and therapeutic approaches to diabetic retinopathy, vitreomacular interface abnormalities, intraocular tumors, posterior uveitis, hereditary retinal degenerations, as well as surgical diseases of the retina.\u003c\/li\u003e\n\u003cli\u003eReview the current and emerging therapeutic approaches for surgical retinal diseases.\u003c\/li\u003e\n\u003cli\u003eEvaluate recent clinical studies evaluating treatments for retinal degenerations.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003eThe \u003cstrong\u003eJohns Hopkins Wilmer Eye Institute’s MACULA and the 5th Annual Retina Festival 2025\u003c\/strong\u003e is tailored for:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eOphthalmologists\u003c\/strong\u003e: Specialists interested in the latest advancements in retinal diseases and treatments.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOptometrists\u003c\/strong\u003e: Professionals seeking to deepen their knowledge of macular and retinal care.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOphthalmic Allied Health Professionals\u003c\/strong\u003e: Individuals involved in supporting retinal diagnostics and therapies.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cbr\u003eThe event focuses on cutting-edge research, imaging techniques, and therapeutic approaches for retinal diseases.\u003cbr\u003e\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e Topics:\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003e*Note: these are continuous video recordings during the conference, they include individual lectures mentioned in the Detail section below\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eChoroidal Neovascularization.mp4\u003cbr\u003eContemporary Retinal Imaging.mp4\u003cbr\u003eDiabetic Macular Edema.mp4\u003cbr\u003eGeographic Atrophy And Inhererited Retinal Diseases.mp4\u003cbr\u003eKeynotes.mp4\u003cbr\u003eMACULA-2025-Program-Jan-7-2025-1430.pdf\u003cbr\u003eOcular Tumors.mp4\u003cbr\u003eProliferative Diabetic Retinopathy.mp4\u003cbr\u003eRetinal Vascular Diseases Other than Diabetic Retinopathy.mp4\u003cbr\u003eSpecial Topics in Retina 2025.mp4\u003c\/li\u003e\n\u003c\/ul\u003e\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e* Detail:\u003cbr\u003e\u003ch3 class=\"boxAgendaTitle\"\u003eSaturday, January 11, 2025\u003c\/h3\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"12u\"\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eWelcome; Conference Goals; Introduction of Keynote Talk\u003c\/strong\u003e\u003cbr\u003e8:00AM – 8:05AM\u003cbr\u003eNeil Bressler, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eWelcome; Conference Goals; Introduction of Keynote Talk\u003c\/strong\u003e\u003cbr\u003e8:00AM – 8:05AM\u003cbr\u003eJ. Fernando Arevalo, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eKeynote Talk: Global Influence of NIH Funded Retina Networks\u003c\/strong\u003e\u003cbr\u003e8:05AM – 8:20AM\u003cbr\u003eDaniel F Martin, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eContemporary Retinal Imaging – MODERATOR\u003c\/strong\u003e\u003cbr\u003e8:20AM – 9:10AM\u003cbr\u003eAmir H Kashani, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eContemporary Retinal Imaging – MODERATOR\u003c\/strong\u003e\u003cbr\u003e8:20AM – 9:10AM\u003cbr\u003eChristina Y. Weng, MD, MBA\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eContemporary Retinal Imaging – MODERATOR\u003c\/strong\u003e\u003cbr\u003e8:20AM – 9:10AM\u003cbr\u003eJohn B Miller, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eHome Monitoring for Age-related Macular Degeneration\u003c\/strong\u003e\u003cbr\u003e8:20AM – 8:30AM\u003cbr\u003eChristina Y. Weng, MD, MBA\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eManaging Retina with OCT Angiography\u003c\/strong\u003e\u003cbr\u003e8:30AM – 8:40AM\u003cbr\u003eAmir H Kashani, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eUltrawide Field Imaging in Diabetic Retinopathy\u003c\/strong\u003e\u003cbr\u003e8:40AM – 8:50AM\u003cbr\u003ePaolo S Silva, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eImaging Geographic Atrophy: Autofluorescence, OCT, Photos\u003c\/strong\u003e\u003cbr\u003e8:50AM – 9:00AM\u003cbr\u003eGlenn Jaffe, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eQuestions and Answers \/ Discussion\u003c\/strong\u003e\u003cbr\u003e9:00AM – 9:10AM\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eGeographic Atrophy and Inherited Retinal Diseases – MODERATOR\u003c\/strong\u003e\u003cbr\u003e9:10AM – 9:40AM\u003cbr\u003eDemetrios Vavvas, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eGeographic Atrophy and Inherited Retinal Diseases – MODERATOR\u003c\/strong\u003e\u003cbr\u003e9:10AM – 9:40AM\u003cbr\u003eMandeep Singh, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eGeographic Atrophy and Inherited Retinal Diseases – MODERATOR\u003c\/strong\u003e\u003cbr\u003e9:10AM – 9:40AM\u003cbr\u003eStephen Tsang, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eTreating Geographic Atrophy: Balancing Benefits and Risks\u003c\/strong\u003e\u003cbr\u003e9:10AM – 9:20AM\u003cbr\u003eDemetrios Vavvas, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eClinical Trials for Inherited Retinal Diseases\u003c\/strong\u003e\u003cbr\u003e9:20AM – 9:30AM\u003cbr\u003eMandeep Singh, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eVitamin Supplements for GA or RP: Vitamin A? Not Today\u003c\/strong\u003e\u003cbr\u003e9:30AM – 9:40AM\u003cbr\u003eJason Comander, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eGene Therapy for Retinal\/Choroidal Vascular Diseases\u003c\/strong\u003e\u003cbr\u003e10:10AM – 10:20AM\u003cbr\u003ePeter A Campochiaro, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eRetinal Vascular Diseases Other Than Diabetic Retinopathy- MODERATOR\u003c\/strong\u003e\u003cbr\u003e10:10AM – 11:10AM\u003cbr\u003eAlexander J Brucker, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eRetinal Vascular Diseases Other Than Diabetic Retinopathy- MODERATOR\u003c\/strong\u003e\u003cbr\u003e10:10AM – 11:10AM\u003cbr\u003eJames Handa, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eRetinal Vascular Diseases Other Than Diabetic Retinopathy- MODERATOR\u003c\/strong\u003e\u003cbr\u003e10:10AM – 11:10AM\u003cbr\u003eSunir Garg, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eMacular Edema from RVO: Does It Matter Which Anti-VEGF\u003c\/strong\u003e\u003cbr\u003e10:20AM – 10:30AM\u003cbr\u003eAleksandra Rachitskaya, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eChallenges of Sickle Cell Retinopathy\u003c\/strong\u003e\u003cbr\u003e10:30AM – 10:40AM\u003cbr\u003eJennifer I Lim, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eTreating MacTel: Just Anatomy or Function Too\u003c\/strong\u003e\u003cbr\u003e10:40AM – 10:50AM\u003cbr\u003eEmily Chew, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eROP and Other Pediatric Retinal Vascular Diseases\u003c\/strong\u003e\u003cbr\u003e10:50AM – 11:00AM\u003cbr\u003eYoshihiro Yonekawa, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eQuestions and Answers \/ Discussion\u003c\/strong\u003e\u003cbr\u003e11:00AM – 11:10AM\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eOcular Tumors\u003c\/strong\u003e\u003cbr\u003e11:10AM – 12:00PM\u003cbr\u003eDavid H Abramson, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eOcular Tumors – MODERATOR\u003c\/strong\u003e\u003cbr\u003e11:10AM – 12:00PM\u003cbr\u003eCarol L Shields, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eOcular Tumors – MODERATOR\u003c\/strong\u003e\u003cbr\u003e11:10AM – 12:00PM\u003cbr\u003eIvana Kim, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eRadiation Retinopathy\u003c\/strong\u003e\u003cbr\u003e11:10AM – 11:20AM\u003cbr\u003eArun D. Singh, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eUpdates on Retinoblastoma and Histiocytosis\u003c\/strong\u003e\u003cbr\u003e11:20AM – 11:30AM\u003cbr\u003eJasmine Francis, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eEvolving Treatments in Choroidal Melanoma\u003c\/strong\u003e\u003cbr\u003e11:30AM – 11:40AM\u003cbr\u003eCarol L Shields, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eOncology Drug Toxicities for the Retina Specialist\u003c\/strong\u003e\u003cbr\u003e11:40AM – 11:50AM\u003cbr\u003eWilliam F Mieler, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eQuestions and Answers \/ Discussion\u003c\/strong\u003e\u003cbr\u003e11:50AM – 12:00PM\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eIntroduction: International Keynote Talk and 100th Celebration\u003c\/strong\u003e\u003cbr\u003e12:55PM – 1:00PM\u003cbr\u003eJ. Fernando Arevalo, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eIntroduction: International Keynote Talk and 100th Celebration\u003c\/strong\u003e\u003cbr\u003e12:55PM – 1:00PM\u003cbr\u003eNeil Bressler, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eInternational Keynote Talk: AI Revolution in Retina\u003c\/strong\u003e\u003cbr\u003e1:00PM – 1:10PM\u003cbr\u003eHaotian Lin, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eChoroidal Neovascularization -MODERATOR\u003c\/strong\u003e\u003cbr\u003e1:10PM – 2:00PM\u003cbr\u003eLucia Sobrin, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eChoroidal Neovascularization -MODERATOR\u003c\/strong\u003e\u003cbr\u003e1:10PM – 2:00PM\u003cbr\u003eAkrit Sodhi, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eChoroidal Neovascularization -MODERATOR\u003c\/strong\u003e\u003cbr\u003e1:10PM – 2:00PM\u003cbr\u003eAdam S Wenick, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eFixed Dosing, As Needed, or Treat and Extend for CNV\u003c\/strong\u003e\u003cbr\u003e1:10PM – 1:20PM\u003cbr\u003eAkrit Sodhi, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003ePolypoidal Choroidal Vasculopathy: Special Considerations\u003c\/strong\u003e\u003cbr\u003e1:20PM – 1:30PM\u003cbr\u003eK. Bailey Freund, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eSafety Considerations: Inflammation \/ Occlusive Vasculitis\u003c\/strong\u003e\u003cbr\u003e1:30PM – 1:40PM\u003cbr\u003eAndre Witkin, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eQuestions and Answers \/ Discussion\u003c\/strong\u003e\u003cbr\u003e1:40PM – 2:00PM\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eProliferative Diabetic Retinopathy – MODERATOR\u003c\/strong\u003e\u003cbr\u003e2:00PM – 2:30PM\u003cbr\u003eK. Bailey Freund, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eProliferative Diabetic Retinopathy – MODERATOR\u003c\/strong\u003e\u003cbr\u003e2:00PM – 2:30PM\u003cbr\u003eJohn Thompson, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eProliferative Diabetic Retinopathy – MODERATOR\u003c\/strong\u003e\u003cbr\u003e2:00PM – 2:30PM\u003cbr\u003eRichard B Rosen, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eProliferative Diabetic Retinopathy: Anti-VEGF, PRP, or Both\u003c\/strong\u003e\u003cbr\u003e2:00PM – 2:10PM\u003cbr\u003eLee M Jampol, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eEvolving Indications for Surgery in Proliferative DR\u003c\/strong\u003e\u003cbr\u003e2:10PM – 2:20PM\u003cbr\u003eDean Eliott, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eQuestions and Answers \/ Discussion\u003c\/strong\u003e\u003cbr\u003e2:20PM – 2:30PM\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eCurrent Role of Fluorescein Angiography in DME\u003c\/strong\u003e\u003cbr\u003e3:00PM – 3:10PM\u003cbr\u003eYannis Mantas Paulus, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eDiabetic Macular Edema – MODERATOR\u003c\/strong\u003e\u003cbr\u003e3:00PM – 4:00PM\u003cbr\u003eMira Sachdeva, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eDiabetic Macular Edema – MODERATOR\u003c\/strong\u003e\u003cbr\u003e3:00PM – 4:00PM\u003cbr\u003eAllen C Ho, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eDiabetic Macular Edema – MODERATOR\u003c\/strong\u003e\u003cbr\u003e3:00PM – 4:00PM\u003cbr\u003eIshrat Ahmed, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eNew Agents for DME: Just Durable or More Durable\u003c\/strong\u003e\u003cbr\u003e3:10PM – 3:20PM\u003cbr\u003eJudy E Kim, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003ePort Delivery System Updates for DME\u003c\/strong\u003e\u003cbr\u003e3:20PM – 3:30PM\u003cbr\u003eCarl D Regillo, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eAI in DME: At Its Infancy or A Flash in the Pan\u003c\/strong\u003e\u003cbr\u003e3:30PM – 3:40PM\u003cbr\u003eT. Y. Alvin Liu, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eApproaches to Prevent Worsening of Diabetic Retinopathy\u003c\/strong\u003e\u003cbr\u003e3:40PM – 3:50PM\u003cbr\u003eNeil Bressler, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eQuestions and Answers \/ Discussion\u003c\/strong\u003e\u003cbr\u003e3:50PM – 4:00PM\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eBig Data and Social Determinants of Health in Retinal Diseases\u003c\/strong\u003e\u003cbr\u003e4:00PM – 4:10PM\u003cbr\u003eCindy X Cai, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eSpecial Topics in Retina for 2025 – MODERATOR\u003c\/strong\u003e\u003cbr\u003e4:00PM – 5:00PM\u003cbr\u003eLee M Jampol, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eSpecial Topics in Retina for 2025 – MODERATOR\u003c\/strong\u003e\u003cbr\u003e4:00PM – 5:00PM\u003cbr\u003eJoseph Anaya, MD, MBA\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eSpecial Topics in Retina for 2025 – MODERATOR\u003c\/strong\u003e\u003cbr\u003e4:00PM – 5:00PM\u003cbr\u003eJose S Pulido, MD, MPH, Professor\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003ePanel Discussion: Women in Retina in 2025\u003c\/strong\u003e\u003cbr\u003e4:10PM – 4:30PM\u003cbr\u003eAdrienne Scott, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003ePanel Discussion: Women in Retina in 2025\u003c\/strong\u003e\u003cbr\u003e4:10PM – 4:30PM\u003cbr\u003eJudy E Kim, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003ePanel Discussion: Women in Retina in 2025\u003c\/strong\u003e\u003cbr\u003e4:10PM – 4:30PM\u003cbr\u003eJasmine Francis, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003ePanel Discussion: Women in Retina in 2025 – MODERATOR\u003c\/strong\u003e\u003cbr\u003e4:10PM – 4:30PM\u003cbr\u003eJennifer I Lim, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eNew Agents for nAMD: Just Durable or More Durable\u003c\/strong\u003e\u003cbr\u003e4:30PM – 4:40PM\u003cbr\u003eSusan Bressler, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eTherapies for Central Serous Chorioretinopathy\u003c\/strong\u003e\u003cbr\u003e4:40PM – 4:50PM\u003cbr\u003eJay Chhablani, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eSummary: MACULA 2025 and Plans for MACULA 2026\u003c\/strong\u003e\u003cbr\u003e4:50PM – 5:00PM\u003cbr\u003eJ. Fernando Arevalo, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eSummary: MACULA 2025 and Plans for MACULA 2026\u003c\/strong\u003e\u003cbr\u003e4:50PM – 5:00PM\u003cbr\u003eNeil Bressler, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954480124002,"sku":"MED-AMB04190","price":40.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Johns-Hopkins-Wilmer-Eye-Institutes-MACULA-and-the-5th-Annual-Retina-Festival-2025.jpg?v=1779377576","url":"https:\/\/meducourse.com\/products\/johns-hopkins-wilmer-eye-institutes-macula-and-the-5th-annual-retina-festival-2025","provider":"Meducourse","version":"1.0","type":"link"}